𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Randomised clinical trial: escitalopram for the prevention of psychiatric adverse events during treatment with peginterferon-alfa-2a and ribavirin for chronic hepatitis C

✍ Scribed by R. J. de Knegt; G. Bezemer; A. R. Van Gool; J. P. H. Drenth; B. E. Hansen; H. A. Droogleever Fortuyn; C. J. Weegink; M. W. Hengeveld; H. L. A. Janssen

Book ID
108606484
Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
250 KB
Volume
34
Category
Article
ISSN
0269-2813

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Placebo-controlled trial of 400 mg amant
Placebo-controlled trial of 400 mg amantadine combined with peginterferon alfa-2a and ribavirin for 48 weeks in chronic hepatitis C virus-1 infection
✍ Michael von Wagner; Wolf Peter Hofmann; Gerlinde Teuber; Thomas Berg; Tobias Goe πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 134 KB πŸ‘ 1 views

The impact of amantadine on virologic response rates of interferon-based treatment of chronic hepatitis C is controversial. The aim of this study was to compare virological response rates in patients with chronic hepatitis C virus (HCV)-1 infection treated with 400 mg amantadine or placebo in combin

PHOENIX: A randomized controlled trial o
PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus
✍ Natalie Bzowej; David R. Nelson; Norah A. Terrault; Gregory T. Everson; Lichen L πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 249 KB πŸ‘ 2 views

The efficacy, tolerability, and safety of the prophylactic treatment of hepatitis C virus (HCV) after liver transplantation (LT) with peginterferon alfa-2a and ribavirin are not known. LT recipients with HCV were randomized to peginterferon alfa-2a/ribavirin treatment or observation 10 to 26 weeks p